Ita-as, Dante U.

HRN: 26-51-57  Sex: Male

Patient Encounter


AMS Audit List

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
01/13/2025
PIPERACILLIN + TAZOBACTAM 2.25G (VIAL)
01/13/2025
01/19/2025
IVT
4.5g As LD Then 2.25g Q6
Q6
ARF Sec To CAP HR And Aspiration Pneumonia
Waiting Final Action 
01/13/2025
CLINDAMYCIN 150MG/ML, 4ML (AMP)
01/13/2025
01/26/2025
IVT
600mg
Q6
ARF Sec To CAP HR And Aspiration Pneumonia
Waiting Final Action 
01/13/2025
MUPIROCIN 2%, 15G (TUBE)
01/13/2025
02/09/2025
TOPICAL
2%, Topical
BID
Decubitus Ulcer
Waiting Final Action 
01/17/2025
CEFTAZIDIME 1GM (VIAL)
01/17/2025
01/23/2025
IV
2g
Q8
Septic Shock
Waiting Final Action 
01/23/2025
PIPERACILLIN + TAZOBACTAM 4.5G (VLS)
01/23/2025
01/30/2025
IV
4.5
Q8
Sepsis
Waiting Final Action 
01/25/2025
SILVER SULFADIAZINE 1%, 25G CREAM (TUBE)
01/25/2025
02/08/2025
TOPICAL
Apply Thin
BID
Decubitus Ulcer
Waiting Final Action 
02/02/2025
LEVOFLOXACIN 5MG/ML, 100ML (VIAL)
02/03/2025
02/19/2025
IV
750 MG
OD
CAP MR
Waiting Final Action 
02/02/2025
CEFTAZIDIME 1GM (VIAL)
02/02/2025
02/22/2025
IV
1g
Q8
CAP-MR; Decubitus Ulcer
Waiting Final Action 
02/11/2025
SILVER SULFADIAZINE 1%, 25G CREAM (TUBE)
02/11/2025
02/18/2025
TOPICAL
Apply Thinlu
BID
Decubitus Ulcer
Waiting Final Action 
02/17/2025
SILVER SULFADIAZINE 1%, 25G CREAM (TUBE)
02/17/2025
02/24/2025
TOPICAL
25G
BID
INFECTIOUS DECUBITUS ULCER
Waiting Final Action 

AMS Audit Form


Start Date: End Date:

Indication:

              

Type of Infection:

                             

           

Compliance to guidelines:



Initial appropriateness:



 If inappropriate:

           

Final appropriateness:



 If inappropriate:

              

Overall appropriateness: